# Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study

> **NCT04605393** · NA · COMPLETED · sponsor: **King's College London** · enrollment: 36 (actual)

## Conditions studied

- Schizophrenia
- Cannabis Use

## Interventions

- **DRUG:** Cannabidiol
- **DRUG:** Placebo
- **DRUG:** Delta-9-THC

## Key facts

- **NCT ID:** NCT04605393
- **Lead sponsor:** King's College London
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-01
- **Primary completion:** 2023-07-07
- **Final completion:** 2023-07-07
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04605393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04605393, "Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT04605393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*